Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ex scientia Ltd
ex scientia Ltd
Activities:
Research & Development
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Ingredients
Transatlantic partnership to screen 15,000 drugs for COVID-19 treatments
Exscientia has announced a joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research
Research & Development
Exscientia initiates sixth AI drug discovery partnership
Exscientia to receive up to CHF67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche
Analysis
Exscientia appoints Georgy Egorov as Chief Financial Officer
Research & Development
Elsevier welcomes six biotech and pharma start-ups to The Hive
Start-ups working on a range of technologies and discoveries — from AI to immunotherapy — receive complimentary access to Elsevier's information solutions to accelerate innovation
Recruitment
Exscientia appoints Alex Snow as Deputy Chairman
Digital
Exscientia enters drug discovery collaboration with GSK
Exscientia, an innovative artificial intelligence driven drug discovery company, has entered into a strategic drug discovery collaboration with GlaxoSmithKline
Research & Development
Collaboration in bispecific-small-molecule drugs for metabolic disease
€250m agreement between Exscientia and Sanofi is for multiple-product development and licence option
Subscribe now